All news

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, benefited, in line with its expectations, from a deferral of orders from major accounts to the third quarter of 2025 and generated revenue of €3.0 million over the period, up from €2.6 million for the same period last year (+18%).

The Spineway Group, a specialist in innovative implants and instruments for the treatment of severe spine disorders, is celebrating its 20th anniversary this year. Throughout its history, the company has demonstrated an unwavering commitment to innovation and offering surgeons more effective technologies to improve quality of life for patients in France and around the world.

Continued improvement in results and financial position / Full-year 2025 growth target confirmed

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, conducted numerous training sessions for surgeons around the world during the first half of 2025. In line with its strategy of international expansion and expertise sharing, the Group organized training courses in Europe, Latin America and Asia, supporting the launch of its product ranges in new markets and consolidating its network of spine surgery professionals.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its subsidiary Spine Innovations has received GMED (French notified body) approval for its new production line dedicated to its LP-ESP and CP-ESP intervertebral disc prostheses. This approval is a significant strategic milestone for the Group, ensuring the manufacturing and supply of its innovative ESP prostheses.

The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Wednesday, June 4, 2025 at 2:00 p.m at the company’s registered office, 7 allée Moulin Berger in Ecully (69).

Spineway informs its shareholders that they are invited to attend the Combined General Meeting to be held on Wednesday, June 4, 2025 at 2:00 p.m. at the Group's headquarters, 7 allée Moulin Berger in Ecully (69).

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.8 million in the first quarter of 2025, stable compared with the fourth quarter of 2024 and down 8% on the revenue for the first quarter of 2024, which constitutes a high comparison base.

• Annual revenue of €12 million (+14%) • Operating income close to breakeven • Reduction in net loss